The Journal of Allergy and Clinical Immunology
Volume 114, Issue 5 , Pages 1183-1188 , November 2004

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants

  • Roland Kaufmann, MD

      Affiliations

    • From Johann Wolfgang Goethe-Universität, Hautklinik, Frankfurt am Main
    • Corresponding Author InformationReprint requests: Roland Kaufmann, MD, Johann Wolfgang Goethe University Hospital, Department of Dermatology and Venereology, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.
    • ,
  • Regina Fölster-Holst, MD

      Affiliations

    • Christian-Albrechts-Universität, Hautklinik, Kiel
    • ,
  • Peter Höger, MD

      Affiliations

    • University of Hamburg, Department of Dermatology, Division of Paediatric Dermatology, Hamburg
    • ,
  • Diamant Thaçi, MD

      Affiliations

    • From Johann Wolfgang Goethe-Universität, Hautklinik, Frankfurt am Main
    • ,
  • Helena Löffler, MD

      Affiliations

    • Novartis Pharma GmbH, Clinical Research, Nürnberg
    • ,
  • Doris Staab, MD

      Affiliations

    • Charite-Virchow Klinikum, Kinderklinik und Poliklinik, Berlin
    • ,
  • Matthias Bräutigam, PhD

      Affiliations

    • Novartis Pharma GmbH, Clinical Research, Nürnberg
    • ,
  • for the CASM981CDE04-Study Group

Received 11 May 2004 ,Revised 6 August 2004 ,Accepted 6 August 2004.

References 

  1. Schultz LF. The epidemiology of atopic dermatitis. Monogr Allergy. 1993;31:9–28
  2. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol. 1994;30:35–39
  3. Wadonda N, Golding J, Kennedy C, et al. Prevalence of atopic eczema in children between 0 and 30 months on Avon district. Br J Dermatol. 2000;143(suppl 57):33
  4. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112(suppl):S118–S127
  5. Boguniewicz M, Eichenfield LF, Hultsch T. Current management of atopic dermatitis and interruption of the atopic march. J Allergy Clin Immunol. 2003;112(suppl):S140–S150
  6. Raimer SS. Managing pediatric atopic dermatitis. Clin Pediatr (Phila). 2000;39:1–14
  7. Gunther S. [Incidence and degree of unwanted adverse effects of corticoids in childhood: results of dermatological studies in children with chronic diseases in the age group of 1-15 years]. Z Hautkr. 1976;51:569–579
  8. Hill CJ, Rostenberg A. Adverse effects from topical steroids. Cutis. 1978;21:624–628
  9. McLean CJ, Lobo RF, Brazier DJ. Cataracts, glaucoma, and femoral avascular necrosis caused by topical corticosteroid ointment. Lancet. 1995;345:330
  10. Queille C, Pommarede R, Saurat JH. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol. 1984;1:246–253
  11. Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C. Cushing's syndrome after topical application of corticosteroids. Am J Dis Child. 1982;136:274–275
  12. Bode HH. Dwarfism following long-term topical corticosteroid therapy. JAMA. 1980;244:813–814
  13. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stutz A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol. 1997;137:568–576
  14. Hultsch T, Muller KD, Meingassner JG, Grassberger M, Schopf RE, Knop J. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res. 1998;290:501–507
  15. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999;141:264–273
  16. Zuberbier T, Chong SU, Grunow K, Guhl S, Welker P, Grassberger M, et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol. 2001;108:275–280
  17. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol. 2001;144:507–513
  18. Wahn U, Bos J, Goodfield M, Caputo R, Papp K, Manjra A, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110:e2
  19. Kapp A, Papp K, Bingham A, Folster-Holst R, Ortonne JP, Potter PC, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol. 2002;110:277–284
  20. Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002;205:271–277
  21. Administration UFaD . Guidance for Industry. E6 good clinical practice: consolidated guidance. Federal Register. 1997;62:25691–25709
  22. Seymour JL, Keswick BH, Hanifin JM, Jordan WP, Milligan MC. Clinical effects of diaper types on the skin of normal infants and infants with atopic dermatitis. J Am Acad Dermatol. 1987;17:988–997
  23. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10:11–18
  24. Barbier N, Paul C, Luger T, Allen R, De Prost Y, Papp K, et al. Validation of the eczema area and severity index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% clinical program. Br J Dermatol. 2004;150:96–102
  25. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46:495–504
  26. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186:23–31
  27. Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195:10–19
  28. Ho VC, Gupta A, Kaufmann R, Todd G, Vanaclocha F, Takaoka R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr. 2003;142:155–162
  29. Reid P, Lewis-Jones MS. Sleep difficulties and their management in preschoolers with atopic eczema. Clin Exp Dermatol. 1995;20:38–41

 Supported by Novartis Pharma GmbH.Conflict of interest statement: The following have a financial interest-relationship as follows. R. Kaufmann: grant-research support from Amgen, Aventis, Basilea, Biofrontera, Biogen, Centocor, Fumapharm, Fujisawa, Galderma, Genmab, Henkel, Hermal, Infectopharm, Leo, Medigene, Medimmune, Novartis, Schering, Schering-Plough, Serono, Smith & Nephew, and Versicor. D. Thaçi: grant-research support from Amgen, Aventis, Basilea, Biofrontera, Biogen, Centocor, Fumapharm, Fujisawa, Galderma, Genmab, Henkel, Hermal, Infectopharm, Leo, Medigene, Medimmune, Novartis, Schering, Schering-Plough, Serono, Smith & Nephew, Versicor; lecture honoraria from Novartis, Biogen, Fumedica, Hermal, Leo; consultant for Novartis and Fujisawa. R. Fölster-Holst: grant-research support from Novartis, Fujisawa, Hartmann and Stallergen; lecture honoraria from Novartis and Fujisawa; consultant for Novartis. P. Höger: grant-research support from Novartis; consultant for Novartis. D. Staab: grant-research support from Novartis and Fujisawa; lecture honoraria from Novartis. H. Löffler and M. Bräutigam are employees of Novartis Pharma GmbH.

PII: S0091-6749(04)02220-1

doi: 10.1016/j.jaci.2004.08.015

The Journal of Allergy and Clinical Immunology
Volume 114, Issue 5 , Pages 1183-1188 , November 2004

Article Tools

* Image Usage & Resolution